Cargando…
Data Mining of the Public Version of the FDA Adverse Event Reporting System
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689877/ https://www.ncbi.nlm.nih.gov/pubmed/23794943 http://dx.doi.org/10.7150/ijms.6048 |
_version_ | 1782274324055457792 |
---|---|
author | Sakaeda, Toshiyuki Tamon, Akiko Kadoyama, Kaori Okuno, Yasushi |
author_facet | Sakaeda, Toshiyuki Tamon, Akiko Kadoyama, Kaori Okuno, Yasushi |
author_sort | Sakaeda, Toshiyuki |
collection | PubMed |
description | The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses. |
format | Online Article Text |
id | pubmed-3689877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-36898772013-06-23 Data Mining of the Public Version of the FDA Adverse Event Reporting System Sakaeda, Toshiyuki Tamon, Akiko Kadoyama, Kaori Okuno, Yasushi Int J Med Sci Review The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses. Ivyspring International Publisher 2013-04-25 /pmc/articles/PMC3689877/ /pubmed/23794943 http://dx.doi.org/10.7150/ijms.6048 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Review Sakaeda, Toshiyuki Tamon, Akiko Kadoyama, Kaori Okuno, Yasushi Data Mining of the Public Version of the FDA Adverse Event Reporting System |
title | Data Mining of the Public Version of the FDA Adverse Event Reporting System |
title_full | Data Mining of the Public Version of the FDA Adverse Event Reporting System |
title_fullStr | Data Mining of the Public Version of the FDA Adverse Event Reporting System |
title_full_unstemmed | Data Mining of the Public Version of the FDA Adverse Event Reporting System |
title_short | Data Mining of the Public Version of the FDA Adverse Event Reporting System |
title_sort | data mining of the public version of the fda adverse event reporting system |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689877/ https://www.ncbi.nlm.nih.gov/pubmed/23794943 http://dx.doi.org/10.7150/ijms.6048 |
work_keys_str_mv | AT sakaedatoshiyuki dataminingofthepublicversionofthefdaadverseeventreportingsystem AT tamonakiko dataminingofthepublicversionofthefdaadverseeventreportingsystem AT kadoyamakaori dataminingofthepublicversionofthefdaadverseeventreportingsystem AT okunoyasushi dataminingofthepublicversionofthefdaadverseeventreportingsystem |